Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 8/20 | 0.69 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.60 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.54 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | HTR2C | P28335 | 2/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 2/20 | 0.50 |
| ▸ | HTR6 | P50406 | 2/20 | 0.50 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.50 |
| ▸ | HTR3B | O95264 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | HTR1D | P28221 | 1/20 | 0.50 |
| ▸ | HTR1B | P28222 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | HTR5A | P47898 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15161248 | 0.88 | NCF1 (0.58) | NCF1ADRB2ADRB1HTR2AHTR2C | |
| SCHEMBL15161240 | 0.85 | SMN1; SMN2 (0.58) | NCF1ADRB2HTR1ATSHRHSD17B10 | |
| SCHEMBL15161269 | 0.84 | SMN1; SMN2 (0.59) | NCF1HTR1ATSHRKDM4EALDH1A1 | |
| SCHEMBL30058953 | 0.82 | NCF1 (0.69) | NCF1ADRB2HTR2AHTR2CSLC6A4 | |
| SCHEMBL2947898 | 0.82 | NCF1 (0.65) | NCF1ADRB2ADRB1HTR2AHTR2C | |
| SCHEMBL15235474 | 0.82 | CYP11B1 (0.51) | NCF1ADRB2SLC6A4CYP1A2CYP2D6 | |
| SCHEMBL2947933 | 0.82 | NCF1 (1.00) | NCF1ADRB2ADRB1HTR2AHTR2C | |
| SCHEMBL16156549 | 0.78 | ADRB1 (0.69) | NCF1ADRB1HTR2AHTR7HTR6 | |
| SCHEMBL5638118 | 0.77 | NCF1 (0.56) | NCF1ADRB2ADRB1HTR2AHTR2C | |
| SCHEMBL29741464 | 0.77 | MAPT (0.79) | NCF1ADRB2HTR2AHTR2CSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621923-B1 | N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES | INTERVET INT BV (NL) | 2017-03-29 | — | — | EP | disclosed |
| US-8883791-B2 | N-heteroaryl compounds with cyclic bridging unit for the treatment of parasitic diseases | INTERVET INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20130203768-A1 | N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES | INTERVET INC. | 2013-08-08 | — | — | US | disclosed |
| EP-2621923-A1 | N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES | Intervet International B.V. (NL) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012041872-A1 | N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES | INTERVET INTERNATIONAL B.V. (NL) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203768-A1 | N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES | PIGO, HNMT, PIGS | NCF1 823/4885ADRB2 1965/4885ADRB1 2373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.